CENTENNIAL, Colo., Aug. 07, 2017 -- Uranium Resources, Inc. (NASDAQ:URRE) will hold a conference call to discuss its second quarter 2017 financial results and recent developments on Monday, August 14, 2017 at 12:30 p.m. Eastern Time (10:30 a.m. Mountain Time).
| Dial-in Numbers: | +1 (800) 319-4610 (U.S. and Canada) |
| +1 (604) 638-5340 (International) | |
| Conference ID: | Uranium Resources Conference Call |
Hosting the call will be Christopher M. Jones, President and Chief Executive Officer of Uranium Resources, who will be joined by Jeffrey L. Vigil, Vice President-Finance and Chief Financial Officer. Mr. Jones will present an overview of the Company’s business position, discuss the Company’s new lithium projects and provide updates on its uranium business. Mr. Vigil will review the financial results.
The conference call and presentation will also be available via a live webcast through the Company’s website, www.uraniumresources.com. A replay of the call will be available on the Company’s website for a limited time and also by phone using the details below.
| Replay Numbers: | +1 (855) 669-9658 (U.S. and Canada) |
| +1 (412) 317-0088 (International) | |
| Code 1617 followed by the # sign. |
About Uranium Resources (URI)
URI is focused on developing energy-related metals. The Company has developed a dominant land position in three prospective lithium brine basins in Nevada and Utah in preparation for exploration and potential development of any resources that may be discovered there. In addition, URI remains focused on advancing the Temrezli in-situ recovery (ISR) uranium project in Central Turkey when uranium prices permit economic development of this project. URI controls extensive exploration properties in Turkey under eight exploration and operating licenses covering approximately 39,000 acres (16,000 ha) with numerous exploration targets, including the potential satellite Sefaatli Project, which is 30 miles (48 km) southwest of the Temrezli Project. In Texas, the Company has two licensed and currently idled processing facilities and approximately 11,000 acres (4,400 ha) of prospective ISR uranium projects. In New Mexico, the Company controls mineral rights encompassing approximately 186,000 acres (75,000 ha) in the prolific Grants Mineral Belt, which is one of the largest concentrations of sandstone-hosted uranium deposits in the world. Incorporated in 1977, URI also owns an extensive uranium information database of historic drill hole logs, assay certificates, maps and technical reports for the Western United States.
Christopher M. Jones, President and CEO 303.531.0472 Jeffrey L. Vigil, VP-Finance and CFO 303.531.0473 Email: [email protected] Website: www.uraniumresources.com


Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



